ArticleTheranostics2021
Aldehyde dehydrogenase inhibitors promote DNA damage in ovarian cancer and synergize with ATM/ATR inhibitors.
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 31 citations in OpenAlex.
- Targeting RPRD1B overcomes chemoresistance in gastric cancer by suppressing the TOPBP1-mediated DNA damage repair pathway.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Aldehyde Detoxification in Cancer: Metabolic Guardians of the Genome.Biomolecules · 2026Review
- Identification of the MRTFA/SRF pathway as a critical regulator of quiescence and chemotherapy resistance in cancer.Cancer letters · 2026Article
- Recent updates and future perspectives about ALDH1B1 as a potential anticancer target: a review.Journal of cancer research and clinical oncology · 2025Review
- C1orf116 inhibits acquired resistance to EGFR inhibitors in EGFR mutant lung adenocarcinoma by suppressing the ATM/ATR pathways.Translational lung cancer research · 2025Article
- Review
- The Significance of Aldehyde Dehydrogenase 1 in Cancers.International journal of molecular sciences · 2024Review
- Alcohol Consumption and Breast and Ovarian Cancer Development: Molecular Pathways and Mechanisms.Current issues in molecular biology · 2024Review
- Targeting Retinaldehyde Dehydrogenases to Enhance Temozolomide Therapy in Glioblastoma.International journal of molecular sciences · 2024Article
- Development of substituted benzimidazoles as inhibitors of human aldehyde dehydrogenase 1A isoenzymes.Chemico-biological interactions · 2024Article
- Multi-Omics profiling identifies aldehyde dehydrogenase 2 as a critical mediator in the crosstalk between Treg-mediated immunosuppression microenvironment and hepatocellular carcinoma.International journal of biological sciences · 2024Article
- The Role of Cancer Stem Cell Markers in Ovarian Cancer.Cancers · 2023Review
- A putative role for ALDH inhibitors and chemoprevention of BRCA-mutation-driven tumors.Gynecologic oncology · 2023Article
- DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities.Cancers · 2023Review
- "DEPHENCE" system-a novel regimen of therapy that is urgently needed in the high-grade serous ovarian cancer-a focus on anti-cancer stem cell and anti-tumor microenvironment targeted therapies.Frontiers in oncology · 2023Review
- Targeting Therapeutic Resistance and Multinucleate Giant Cells in CCNE1-Amplified HR-Proficient Ovarian Cancer.Molecular cancer therapeutics · 2022Article
- Structural and biochemical evidence that ATP inhibits the cancer biomarker human aldehyde dehydrogenase 1A3.Communications biology · 2022Article
- Recent Advances in Synergistic Antitumor Effects Exploited from the Inhibition of Ataxia Telangiectasia and RAD3-Related Protein Kinase (ATR).Molecules (Basel, Switzerland) · 2022Review
- Cancer Stem Cells in Ovarian Cancer-A Source of Tumor Success and a Challenging Target for Novel Therapies.International journal of molecular sciences · 2022Review
- Precision Medicine forCancers · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Edward GrimleyDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, UPMC Hillman Cancer Center and the Magee-Womens Research Institute, University of Pittsburgh, Pittsburgh, PA, USA.
Alexander J ColeDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, UPMC Hillman Cancer Center and the Magee-Womens Research Institute, University of Pittsburgh, Pittsburgh, PA, USA.
Thong T LuongDept of Microbiology and Molecular. Genetics, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Stacy C McGonigalDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, UPMC Hillman Cancer Center and the Magee-Womens Research Institute, University of Pittsburgh, Pittsburgh, PA, USA.
Sarah SinnoDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, UPMC Hillman Cancer Center and the Magee-Womens Research Institute, University of Pittsburgh, Pittsburgh, PA, USA.
Dongli YangDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, UPMC Hillman Cancer Center and the Magee-Womens Research Institute, University of Pittsburgh, Pittsburgh, PA, USA.
Kara A BernsteinDept of Microbiology and Molecular. Genetics, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Ronald J BuckanovichDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, UPMC Hillman Cancer Center and the Magee-Womens Research Institute, University of Pittsburgh, Pittsburgh, PA, USA.
Magee-Womens Research Institute · USUPMC Hillman Cancer Center · USUniversity of Pittsburgh · US
Funding
Replication fork dynamics and repair by Rad51 paralogues after DNA alkylationR01ES030335 · NIEHS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Kara A Bernstein · 2019 to 2026
$2.9MALDH Inhibition as Modulator of Tumor ImmunobiologyR01CA238315 · NCI · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI BUCKANOVICH, RONALD J, CASCIO, SANDRA · 2020 to 2024
$2.2MRAD51 paralog function in cancer predisposition and genome integrity R01ES031796 · NIEHS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BERNSTEIN, KARA A · 2021 to 2025
$2.2MIsozyme-selective ALDH Inhibitors for Sensitizing Ovarian Cancer Stem-like Cells to ChemotherapyR01CA214567 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BUCKANOVICH, RONALD J, LARSEN, SCOTT D · 2017 to 2019
$1.8MNCI NIH HHS R01 CA214567NCI NIH HHS R01 CA238315NIEHS NIH HHS R01 ES030335NIEHS NIH HHS R01 ES031796
Abstract
PubMed holds no abstract for this paper.
Indexed as
DNA DamageAldehyde Dehydrogenase 1 FamilyAldehyde OxidoreductasesAldehydesAnimalsAtaxia Telangiectasia Mutated ProteinsCell Line, TumorDNA Breaks, Double-StrandedDrug SynergismEnzyme InhibitorsFemaleGene Knockout TechniquesHumansMiceOvarian NeoplasmsPrecision MedicineAldehyde Dehydrogenase 1 Familyaldehyde dehydrogenase (NAD(P)+)Aldehyde OxidoreductasesAldehydesAtaxia Telangiectasia Mutated ProteinsATM protein, humanATR protein, humanEnzyme InhibitorsProtein Kinase Inhibitorsaldehyde dehydrogenaseATMATRDNA damageOvarian cancer
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.